FSD Stock Recent News

Denver, Colorado--(Newsfile Corp. - July 23, 2024) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report highlighting small cap market biotech developments, featuring FSD Pharma (NASDAQ: HUGE). FSD Pharma (NASDAQ: HUGE) To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10481/217432_2c52394c544c9bc9_logo_lg.jpg To read the full article on 247marketnews.com, please click here The report discusses FSD Pharma's revolutionary rapid alcohol detoxification drink, UNBUZZD™, which helps to rapidly restore mental alertness post-alcohol consumption.

This article discusses the upcoming merger of First Trust High Income Long/Short Fund into abrdn Income Credit Strategies Fund. The merger of FSD into ACP was approved, with shares to de-list on July 19, 2024. FSD shareholders to receive NAV for NAV shares in ACP, which is trading at a premium to NAV.

PHILADELPHIA, PA / ACCESSWIRE / July 9, 2024 / The Board of Trustees of abrdn Income Credit Strategies Fund (NYSE:ACP) ("ACP" or the "Acquiring Fund") previously announced that shareholders of First Trust High Income Long/Short Fund (NYSE:FSD) ("FSD" or the "Acquired Fund"), advised by First Trust Advisors L.P., have approved the proposed reorganization into ACP ("Reorganization") and today announces that the Reorganization is expected to close at the close of business on July 19, 2024, subject to the satisfaction of customary closing conditions.

Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced today that it has filed an amended and restated its material change report dated December 7, 2023 (the "Original MCR"), in order to amend the disclosure in Section 5.1 of the Original MCR. The amended and restated material change report (the "Amended and Restated MCR") is being filed to provide additional disclosure with respect of the private placement offering of Class A Multiple Voting Shares of the Company (the "MVS") that closed on December 5, 2023 (the "Offering").

WHEATON, Ill.--(BUSINESS WIRE)--First Trust Advisors L.P. (“FTA”) previously announced that shareholders of First Trust High Income Long/Short Fund (NYSE: FSD) (“FSD”), a diversified, closed-end management investment company organized as a Massachusetts business trust, have approved the reorganization of FSD with and into abrdn Income Credit Strategies Fund (“ACP”), a diversified, closed-end management investment company organized as a Delaware statutory trust. Subject to the satisfaction of ce.

TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update. Corporate Update FSD Pharma has retained the services of Totaligent, Inc. ("Totaligent") who will play a key role in assisting the Company to enhance its market awareness and foster productive, continuing dialogues with shareholders and other market participants.

TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on June 27, 2024, the United States District Court for the Eastern District of Pennsylvania confirmed FSD Pharma, Inc.'s motion for entry of judgment is granted and judgment is entered in favour of FSD Pharma and against Dr. Raza Bokhari as follows: USD $147,301.04, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied. CAD $31,912.55, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied.

TORONTO, ON / ACCESSWIRE / June 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it has received approval by the human ethics review committee (HREC) in Australia for its trial entitled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants." Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis (MS).

WHEATON, Ill.--(BUSINESS WIRE)--First Trust High Income Long/Short Fund (the "Fund") (NYSE: FSD) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.105 per share payable on July 15, 2024, to shareholders of record as of July 1, 2024. The ex-dividend date is expected to be July 1, 2024. The monthly distribution information for the Fund appears below. First Trust High Income Long/Short Fund (FSD): Distribution per share:.

TORONTO, ON / ACCESSWIRE / June 13, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it entered into an exclusive option agreement with the University of Southern California (USC) to evaluate dietary supplement technology for commercialization. The option agreement, signed June 11, 2024, allows FSD Pharma to exclusively evaluate the novel technology for a 6-month term.